Last update 01 Nov 2024

survivin x CMV pp65 x EphA2

Basic Info

Related Targets
survivinCMV pp65EphA2

Related

1
Drugs associated with survivin x CMV pp65 x EphA2
P30-EPS vaccine(Duke University)
Target
CMV pp65 x EphA2 x survivin
Mechanism
CMV pp65 modulators [+3]
Active Org.
National Cancer InstituteNational Cancer Institute
Originator Org.
Duke UniversityDuke University
Active Indication
Glioblastoma Multiforme
Inactive Indication-
Drug Highest PhasePhase 1
First Approval Ctry. / Loc.-
First Approval Date20 Jan 1800
1
Clinical Trials associated with survivin x CMV pp65 x EphA2
NCT05283109 / RecruitingPhase 1IIT
ETAPA I: Evaluation of Tumor Associated P30-Peptide Antigen I; A Pilot Trial of Peptide-based Tumor Associated Antigen Vaccines in Newly Diagnosed, Unmethylated, and Untreated Glioblastoma (GBM)
100 Clinical Results associated with survivin x CMV pp65 x EphA2
Login to view more data
100 Translational Medicine associated with survivin x CMV pp65 x EphA2
Login to view more data
0 Patents (Medical) associated with survivin x CMV pp65 x EphA2
Login to view more data

Analysis

Perform a panoramic analysis of this field.
login
or
view full example data
Perform a panoramic analysis of this field.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free